## Taishiro Kishimoto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7447915/publications.pdf

Version: 2024-02-01

130 papers 6,601 citations

38 h-index 77 g-index

142 all docs

142 docs citations

times ranked

142

7267 citing authors

#	Article	lF	CITATIONS
1	Efficacy and safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis. Psychological Medicine, 2023, 53, 4064-4082.	4.5	9
2	Advantages and disadvantages of the long-term use of telepsychiatry. Irish Journal of Psychological Medicine, 2023, 40, 538-539.	1.0	3
3	Changes in telepsychiatry regulations during the COVID-19 pandemic: 17 countries and regions' approaches to an evolving healthcare landscape. Psychological Medicine, 2022, 52, 2606-2613.	4.5	72
4	Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A). Journal of Affective Disorders, 2022, 299, 367-376.	4.1	33
5	The characteristics of patients receiving psychotropic pro re nata medication at discharge for the treatment of schizophrenia and major depressive disorder: A nationwide survey from the EGUIDE project. Asian Journal of Psychiatry, 2022, 69, 103007.	2.0	12
6	Subjective assessment of participants in education programs on clinical practice guidelines in the field of psychiatry. Neuropsychopharmacology Reports, 2022, 42, 221-225.	2.3	12
7	Current Status and Challenges of the Dissemination of Telemedicine in Japan After the Start of the COVID-19 Pandemic. Telemedicine Journal and E-Health, 2022, 28, 1220-1224.	2.8	5
8	A dissemination and education programme to improve the clinical behaviours of psychiatrists in accordance with treatment guidelines for schizophrenia and major depressive disorders: the Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project. BJPsych Open, 2022, 8, e83.	0.7	11
9	Characteristics of single-channel electroencephalogram in depression during conversation with noise reduction technology. PLoS ONE, 2022, 17, e0266518.	2.5	1
10	Clozapine Treatment Is Associated With Higher Prescription Rate of Antipsychotic Monotherapy and Lower Prescription Rate of Other Concomitant Psychotropics: A Real-World Nationwide Study. International Journal of Neuropsychopharmacology, 2022, 25, 818-826.	2.1	11
11	Association of work environment with stress and depression among Japanese workers. Work, 2022, , 1-15.	1.1	2
12	Neuronal network mechanisms associated with depressive symptom improvement following electroconvulsive therapy. Psychological Medicine, 2021, 51, 2856-2863.	4.5	16
13	Effects of Psychotropics on the Microbiome in Patients With Depression and Anxiety: Considerations in a Naturalistic Clinical Setting. International Journal of Neuropsychopharmacology, 2021, 24, 97-107.	2.1	24
14	Electroconvulsive Therapy for Parkinson's Disease: A Systematic Review and Metaâ€Analysis. Movement Disorders, 2021, 36, 50-58.	3.9	47
15	Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study.  Neuropsychopharmacology Reports, 2021, 41, 199-206.	2.3	17
16	Unobtrusive Sensing Technology for Quantifying Stress and Well-Being Using Pulse, Speech, Body Motion, and Electrodermal Data in a Workplace Setting: Study Concept and Design. Frontiers in Psychiatry, 2021, 12, 611243.	2.6	7
17	Electroconvulsive Therapy for Patients With Depression Who Lack Capacity for Consent. Journal of ECT, 2021, 37, 171-175.	0.6	4
18	Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies. Lancet Psychiatry,the, 2021, 8, 387-404.	7.4	160

#	Article	IF	CITATIONS
19	Personalization of Repetitive Transcranial Magnetic Stimulation for the Treatment of Major Depressive Disorder According to the Existing Psychiatric Comorbidity. Clinical Psychopharmacology and Neuroscience, 2021, 19, 190-205.	2.0	20
20	Gastrointestinal symptoms and sensory abnormalities associated with behavioral problems in children with neurodevelopmental disorders. Autism Research, 2021, 14, 1996-2001.	3.8	5
21	Long-acting injectable versus oral antipsychotics for schizophrenia – Authors' reply. Lancet Psychiatry,the, 2021, 8, 567.	7.4	2
22	Elevated body weight modulates subcortical volume change and associated clinical response following electroconvulsive therapy. Journal of Psychiatry and Neuroscience, 2021, 46, E418-E426.	2.4	4
23	Long-acting antipsychotics: is what we know really so? – Authors' reply. Lancet Psychiatry,the, 2021, 8, 651-652.	7.4	O
24	Fecal Microbial and Metabolomic Change during treatment course for depression: An Observational Study. Journal of Psychiatric Research, 2021, 140, 45-52.	3.1	10
25	Association of electroconvulsive therapy-induced structural plasticity with clinical remission. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 110, 110286.	4.8	8
26	Subjective well-being and month-long LF/HF ratio among deskworkers. PLoS ONE, 2021, 16, e0257062.	2.5	8
27	What Can We Tell About the Effect of Electroconvulsive Therapy on the Human Hippocampus?. Clinical EEG and Neuroscience, 2021, , 155005942110440.	1.7	1
28	OUP accepted manuscript. Schizophrenia Bulletin, 2021, , .	4.3	1
29	Response to Morina et al.'s criticisms of Horigome et al.'s recent report on the efficacy of virtual reality exposure therapy for social anxiety disorder. Psychological Medicine, 2021, , 1-2.	4.5	0
30	Japanese Project for Telepsychiatry Evaluation during COVID-19: Treatment Comparison Trial (J-PROTECT): Rationale, design, and methodology. Contemporary Clinical Trials, 2021, 111, 106596.	1.8	7
31	Autism Spectrum Disorder's Severity Prediction Model Using Utterance Features for Automatic Diagnosis Support. Studies in Computational Intelligence, 2020, , 83-95.	0.9	4
32	Brain Changes Induced by Electroconvulsive Therapy Are Broadly Distributed. Biological Psychiatry, 2020, 87, 451-461.	1.3	72
33	Large-Scale Dialog Corpus Towards Automatic Mental Disease Diagnosis. Studies in Computational Intelligence, 2020, , 111-118.	0.9	2
34	Remote neuropsychological assessment of elderly Japanese population using the Alzheimer's Disease Assessment Scale: A validation study. Journal of Telemedicine and Telecare, 2020, 26, 482-487.	2.7	18
35	A Validation Study of the Remotely Administered Montreal Cognitive Assessment Tool in the Elderly Japanese Population. Telemedicine Journal and E-Health, 2020, 26, 920-928.	2.8	32
36	Unmet needs of patients with major depressive disorder – Findings from the â€~ <scp>E</scp> ffectiveness of <scp>G</scp> uidelines for <scp>D</scp> issemination and <scp>E</scp> ducation in <scp>P</scp> sychiatric <scp>T</scp> reatment ( <scp>EGUIDE</scp> )' project: A nationwide dissemination, education, and evaluation study. Psychiatry and Clinical Neurosciences, 2020, 74, 667-669.	1.8	20

#	Article	IF	CITATIONS
37	Virtual reality exposure therapy for social anxiety disorder: a systematic review and meta-analysis. Psychological Medicine, 2020, 50, 2487-2497.	4.5	64
38	Predicting Individual Remission After Electroconvulsive Therapy Based on Structural Magnetic Resonance Imaging. Journal of ECT, 2020, 36, 205-210.	0.6	6
39	The project for objective measures using computational psychiatry technology (PROMPT): Rationale, design, and methodology. Contemporary Clinical Trials Communications, 2020, 19, 100649.	1.1	8
40	P.318 Safety/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis. European Neuropsychopharmacology, 2020, 40, S184-S185.	0.7	0
41	P.556 Long-acting injectable vs. oral antipsychotics for preventing rehospitalisation in schizophrenia: a meta-analysis of randomised, mirror-image, and cohort studies. European Neuropsychopharmacology, 2020, 40, S315-S316.	0.7	0
42	Examination of Language Characteristics Among Patients With Alzheimer's Disease Using Natural Language Processing. Biological Psychiatry, 2020, 87, S285.	1.3	0
43	Using speech recognition technology to investigate the association between timing-related speech features and depression severity. PLoS ONE, 2020, 15, e0238726.	2.5	27
44	Effects of Psychotropics on the Microbiome in Patients With Depression and Anxiety: a Naturalistic Prospective Study. Biological Psychiatry, 2020, 87, S279-S280.	1.3	0
45	Prescription patterns in patients with schizophrenia in Japan: Firstâ€quality indicator data from the survey of "Effectiveness of Guidelines for Dissemination and Education in psychiatric treatment (EGUIDE)―project. Neuropsychopharmacology Reports, 2020, 40, 281-286.	2.3	32
46	Speech Quality Feature Analysis for Classification of Depression and Dementia Patients. Sensors, 2020, 20, 3599.	3.8	16
47	Evaluating depression with multimodal wristband-type wearable device: screening and assessing patient severity utilizing machine-learning. Heliyon, 2020, 6, e03274.	3.2	58
48	Evaluating the severity of depressive symptoms using upper body motion captured by RGB-depth sensors and machine learning in a clinical interview setting: A preliminary study. Comprehensive Psychiatry, 2020, 98, 152169.	3.1	9
49	Gut microbiota and major depressive disorder: A systematic review and meta-analysis. Journal of Affective Disorders, 2020, 266, 1-13.	4.1	217
50	Thalamic volume, resting-state activity, and their association with the efficacy of electroconvulsive therapy. Journal of Psychiatric Research, 2019, 117, 135-141.	3.1	13
51	Psychiatrists' perceptions of medication adherence among patients with schizophrenia: An international survey. Schizophrenia Research, 2019, 211, 105-107.	2.0	1
52	Survey of the effects of internet usage on the happiness of Japanese university students. Health and Quality of Life Outcomes, 2019, 17, 151.	2.4	15
53	Facial Landmark Activity Features for Depression Screening. , 2019, , .		5
54	F128. Structural Magnetic Resonance Imaging for Individual Predictions for Electroconvulsive Therapy Remission Utilizing Machine Learning. Biological Psychiatry, 2019, 85, S263.	1.3	0

#	Article	IF	CITATIONS
55	Improvement of psychiatrists' clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the â€~Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)' project: A nationwide dissemination, education, and evaluation study. Psychiatry and Clinical Neurosciences, 2019, 73, 642-648.	1.8	35
56	Acute and long-term effects of electroconvulsive therapy on human dentate gyrus. Neuropsychopharmacology, 2019, 44, 1805-1811.	5.4	48
57	Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: A systematic review and meta-analysis. Schizophrenia Research, 2019, 209, 50-57.	2.0	27
58	Longâ€term effectiveness of oral secondâ€generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and metaâ€analysis of direct headâ€toâ€head comparisons. World Psychiatry, 2019, 18, 208-224.	10.4	93
59	Actigraphy for evaluation of mood disorders: A systematic review and meta-analysis. Journal of Affective Disorders, 2019, 253, 257-269.	4.1	88
60	Electroconvulsive Therapy Modulates Resting-State EEG Oscillatory Pattern and Phase Synchronization in Nodes of the Default Mode Network in Patients With Depressive Disorder. Frontiers in Human Neuroscience, 2019, 13, 1.	2.0	133
61	Attitudes Toward Electroconvulsive Therapy Among Involuntary and Voluntary Patients. Journal of ECT, 2019, 35, 165-169.	0.6	25
62	Volume Increase of the Dentate Gyrus Induced by Electroconvulsive Therapy. Journal of ECT, 2019, 35, e57-e58.	0.6	13
63	Long-Acting Injectables Versus Oral Antipsychotics. Journal of Clinical Psychopharmacology, 2019, 39, 441-445.	1.4	15
64	Effectiveness and safety of long-term benzodiazepine use in anxiety disorders. International Clinical Psychopharmacology, 2019, 34, 211-221.	1.7	23
65	Prolonged Post–Electroconvulsive Therapy Delirium Controlled With Donepezil. Journal of ECT, 2019, 35, e29-e30.	0.6	4
66	Glutamatergic neurometabolite levels in major depressive disorder: a systematic review and meta-analysis of proton magnetic resonance spectroscopy studies. Molecular Psychiatry, 2019, 24, 952-964.	7.9	225
67	F78. The Effect of Fecal Microbiota Transplantation on Psychiatric Symptoms Among Patients With Functional Gastrointestinal Disorders: An Open-Label Observational Study. Biological Psychiatry, 2018, 83, S268.	1.3	0
68	Associations between problematic Internet use and psychiatric symptoms among university students in Japan. Psychiatry and Clinical Neurosciences, 2018, 72, 531-539.	1.8	90
69	The effect of fecal microbiota transplantation on psychiatric symptoms among patients with irritable bowel syndrome, functional diarrhea and functional constipation: An open-label observational study. Journal of Affective Disorders, 2018, 235, 506-512.	4.1	134
70	Effect of electroconvulsive therapy on hippocampal and amygdala volumes: systematic review and meta-analysis. British Journal of Psychiatry, 2018, 212, 19-26.	2.8	94
71	Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. Schizophrenia Bulletin, 2018, 44, 603-619.	4.3	137
72	Utilization of Facial Image Analysis Technology for Blink Detection: A Validation Study. Eye and Contact Lens, 2018, 44, S297-S301.	1.6	0

#	Article	IF	CITATIONS
73	Sleep Disorders are a Prevalent and Serious Comorbidity in Dry Eye. , 2018, 59, DES143.		38
74	The Relationship of Dry Eye Disease with Depression and Anxiety: A Naturalistic Observational Study. Translational Vision Science and Technology, 2018, 7, 35.	2.2	39
75	Minocycline as a treatment for schizophrenia: is the discussion truly finished?. Lancet Psychiatry,the, 2018, 5, 856-857.	7.4	12
76	T154. Electroconvulsive Therapy Induces Age-Dependent Volume Increase in the Human Dentate Gyrus. Biological Psychiatry, 2018, 83, S188.	1.3	2
77	An estimation of heart rate variability from ballistocardiogram measured with bed leg sensors. , 2018, , .		2
78	A practical BCG measuring system with bed sensors and algorithm for heartbeat detection. , 2018, , .		6
79	Internet-Based Cognitive Behavioral Therapy With Real-Time Therapist Support via Videoconference for Patients With Obsessive-Compulsive Disorder, Panic Disorder, and Social Anxiety Disorder: Pilot Single-Arm Trial. Journal of Medical Internet Research, 2018, 20, e12091.	4.3	52
80	Comparison of treatment patterns in schizophrenia between China and Japan (2001â€2009). Asia-Pacific Psychiatry, 2017, 9, e12277.	2.2	5
81	Regulation of striatal dopamine responsiveness by Notch/RBP-J signaling. Translational Psychiatry, 2017, 7, e1049-e1049.	4.8	11
82	Indications for and use of long-acting injectable antipsychotics. International Clinical Psychopharmacology, 2017, 32, 161-168.	1.7	13
83	Bifidobacterium-Rich Fecal Donor May Be a Positive Predictor for Successful Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome. Digestion, 2017, 96, 29-38.	2.3	266
84	Smartphone viewing distance and sleep: an experimental study utilizing motion capture technology. Nature and Science of Sleep, 2017, Volume 9, 59-65.	2.7	44
85	Sleep and mood disorders in dry eye disease and allied irritating ocular diseases. Scientific Reports, 2016, 6, 22480.	3.3	58
86	Single-dose infusion ketamine and non-ketamine <i>N</i> -methyl- <scp>d</scp> -aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychological Medicine, 2016, 46, 1459-1472.	4.5	292
87	Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophrenia Research, 2016, 176, 220-230.	2.0	97
88	Predictors of readmission after successful electroconvulsive therapy for depression: a chart review study. International Journal of Psychiatry in Clinical Practice, 2016, 20, 260-264.	2.4	4
89	Sleep and mood disorders in women with dry eye disease. Scientific Reports, 2016, 6, 35276.	3.3	28
90	Worldwide Differences in Regulations of Clozapine Use. CNS Drugs, 2016, 30, 149-161.	5.9	139

#	Article	IF	CITATIONS
91	Factors associated with discontinuation of aripiprazole treatment after switching from other antipsychotics in patients with chronic schizophrenia: A prospective observational study. Psychiatry Research, 2016, 236, 71-74.	3.3	13
92	Attenuated psychotic and basic symptom characteristics in adolescents with ultra-high risk criteria for psychosis, other non-psychotic psychiatric disorders and early-onset psychosis. European Child and Adolescent Psychiatry, 2016, 25, 1091-1102.	4.7	26
93	A Survey of Japanese Young Adults' Postures When Using Smartphones before Sleeping. Journal of Mobile Technology in Medicine, 2016, 5, 51-53.	0.5	2
94	P.3.d.067 Long-acting injectable vs oral antipsychotics for hospitalisation prevention in schizophrenia: a systematic review/meta-analysis of cohort studies. European Neuropsychopharmacology, 2015, 25, S519.	0.7	0
95	Ambiguous findings concerning potential advantages of depot antipsychotics. Current Opinion in Psychiatry, 2015, 28, 216-221.	6.3	47
96	Transcranial Magnetic Stimulation for Bipolar Disorder with Catatonic Stupor: A Case Report. Brain Stimulation, 2015, 8, 1236-1237.	1.6	7
97	Frequency and Correlates of <em>DSM-5</em> Attenuated Psychosis Syndrome in a Sample of Adolescent Inpatients With Nonpsychotic Psychiatric Disorders. Journal of Clinical Psychiatry, 2015, 76, e1449-e1458.	2.2	20
98	The Bipolar Prodrome Symptom Interview and Scale–Prospective ( <scp>BPSS</scp> â€P): description and validation in a psychiatric sample and healthy controls. Bipolar Disorders, 2014, 16, 505-522.	1.9	77
99	Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials. Schizophrenia Bulletin, 2014, 40, 192-213.	4.3	332
100	Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. Journal of Clinical Epidemiology, 2013, 66, S37-S41.	5.0	109
101	The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: Findings from a longitudinal observational cohort. Schizophrenia Research, 2013, 147, 383-386.	2.0	26
102	Antipsychotic polypharmacy: A Japanese survey of prescribers' attitudes and rationales. Psychiatry Research, 2013, 209, 406-411.	3.3	28
103	Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Molecular Psychiatry, 2013, 18, 53-66.	7.9	136
104	Adjunctive Use of Nonsteroidal Anti-inflammatory Drugs for Schizophrenia: A Meta-analytic Investigation of Randomized Controlled Trials. Schizophrenia Bulletin, 2013, 39, 1230-1241.	4.3	168
105	Deficits in microRNA-mediated Cxcr4/Cxcl12 signaling in neurodevelopmental deficits in a 22q11 deletion syndrome mouse model. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 17552-17557.	7.1	65
106	Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry, 2013, 12, 216-226.	10.4	356
107	Early Nonresponse Determined by the Clinical Global Impressions Scale Predicts Poorer Outcomes in Youth with Schizophrenia Spectrum Disorders Naturalistically Treated with Second-Generation Antipsychotics. Journal of Child and Adolescent Psychopharmacology, 2013, 23, 665-675.	1.3	30
108	Long-Acting Injectable Versus Oral Antipsychotics in Schizophrenia. Journal of Clinical Psychiatry, 2013, 74, 957-965.	2.2	371

#	Article	IF	CITATIONS
109	An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia. Neuropsychiatric Disease and Treatment, 2013, 9, 1553.	2.2	2
110	Osteoporosis and fracture risk in people with schizophrenia. Current Opinion in Psychiatry, 2012, 25, 415-429.	6.3	91
111	P.3.c.033 Long-acting injectable vs. oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image and cohort studies. European Neuropsychopharmacology, 2012, 22, S335-S336.	0.7	4
112	The 3rd Schizophrenia International Research Society Conference, 14–18 April 2012, Florence, Italy: Summaries of oral sessions. Schizophrenia Research, 2012, 141, e1-e24.	2.0	8
113	Antipsychotic polypharmacy: A survey study of prescriber attitudes, knowledge and behavior. Schizophrenia Research, 2011, 131, 58-62.	2.0	78
114	P1-485 Expanding between-school differences in smoking prevalence of high school students in Japan. Journal of Epidemiology and Community Health, 2011, 65, A201-A201.	3.7	0
115	Quantifying Clinical Relevance in the Treatment of Schizophrenia. Clinical Therapeutics, 2011, 33, B16-B39.	2.5	94
116	Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. Dialogues in Clinical Neuroscience, 2011, 13, 155-172.	3.7	38
117	Review: most antipsychotic drugs more than double the prolactin levels in children and adolescents. Evidence-Based Mental Health, 2010, 13, 54-54.	4.5	1
118	Antipsychotic-Induced Hyperprolactinemia Inhibits the Hypothalamo-Pituitary-Gonadal Axis and Reduces Bone Mineral Density in Male Patients With Schizophrenia. Journal of Clinical Psychiatry, 2008, 69, 385-391.	2.2	86
119	Antipsychotic-induced amenorrhea might lead to loss of bone mineral density. International Clinical Psychopharmacology, 2005, 20, A14.	1.7	0
120	Bone mineral density measurement in female inpatients with schizophrenia. Schizophrenia Research, 2005, 77, 113-115.	2.0	15
121	Probable Dementia with Lewy Bodies and Risperidone-Induced Delirium. Canadian Journal of Psychiatry, 2002, 47, 976-976.	1.9	12
122	Angiotensinogen Gene Variation and Hypertension in a Cohort Study in Japanese Journal of Epidemiology, 2001, 11, 115-119.	2.4	13
123	Deletion of Crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nature Genetics, 2000, 24, 415-419.	21.4	477
124	Hepatoid adenocarcinoma: a new clinicopathological entity and the hypotheses on carcinogenesis. Medical Electron Microscopy: Official Journal of the Clinical Electron Microscopy Society of Japan, 2000, 33, 57-63.	1.8	36
125	PCCX1, a Novel DNA-Binding Protein with PHD Finger and CXXC Domain, Is Regulated by Proteolysis. Biochemical and Biophysical Research Communications, 2000, 271, 305-310.	2.1	5
126	A sauvagine/corticotropin-releasing factor receptor expressed in heart and skeletal muscle Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 1108-1112.	7.1	358

## Taishiro Kishimoto

#	Article	IF	CITATIONS
127	5-HT1A receptor-mediated inhibition of lateral vestibular nucleus neurons projecting to the abducens nucleus. Brain Research, 1994, 644, 47-51.	2.2	15
128	Inhibition of lateral vestibular nucleus neurons by 5-hydroxytryptamine derived from the dorsal raphe nucleus. Brain Research, 1991, 553, 229-237.	2.2	20
129	RENAL AND PELVIC ARTERIOGRAPHY. Japanese Journal of Urology, 1954, 45, 136-146.	0.1	1
130	RENAL AND PELVIC ARTERIOGRAPHY. Japanese Journal of Urology, 1954, 45, 404-416.	0.1	0